Truist Financial Has Lowered Expectations for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART - Free Report) had its price target cut by Truist Financial from $26.00 to $19.00 in a research note published on Friday,Benzinga reports. They currently have a hold rating on the life sciences company's stock.

Separately, Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Integra LifeSciences has a consensus rating of "Hold" and a consensus target price of $22.71.

Integra LifeSciences Trading Down 3.9 %

NASDAQ:IART traded down $0.65 during midday trading on Friday, hitting $16.08. The stock had a trading volume of 725,546 shares, compared to its average volume of 1,049,540. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock has a 50-day moving average of $22.08 and a 200 day moving average of $22.34. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -178.65, a PEG ratio of 0.73 and a beta of 1.24. Integra LifeSciences has a one year low of $15.95 and a one year high of $33.04.

Remove Ads

Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. The firm had revenue of $442.65 million during the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The firm's quarterly revenue was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.89 earnings per share. As a group, sell-side analysts forecast that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. Principal Financial Group Inc. lifted its stake in Integra LifeSciences by 18.7% during the 3rd quarter. Principal Financial Group Inc. now owns 401,432 shares of the life sciences company's stock valued at $7,294,000 after acquiring an additional 63,266 shares during the period. Norges Bank purchased a new position in shares of Integra LifeSciences during the 4th quarter valued at about $8,967,000. Nisa Investment Advisors LLC lifted its holdings in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after buying an additional 2,800 shares during the period. PNC Financial Services Group Inc. grew its holdings in Integra LifeSciences by 33.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 19,755 shares of the life sciences company's stock worth $448,000 after acquiring an additional 4,967 shares during the period. Finally, Empowered Funds LLC purchased a new position in Integra LifeSciences during the fourth quarter valued at approximately $180,000. Institutional investors and hedge funds own 84.78% of the company's stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.